Protein tyrosine phosphatases (PTP) are emerging drug targets for the prevention and/or treatment of cancer, diabetes, autoimmune diseases and other common human ailments. High throughput screening (HTS) for PTP inhibitors is currently performed using enzyme-based assays and simple non-peptide phosphotyrosine (pTyr) analogs, such as para-nitrophenylphosphate (p-NPP) and 6,8-difluoro-4-methylumbiliferyl phosphate (DiFMUP). An obvious limitation of these universal substrates is their lack of enzyme specificity. Also at present none of the available PTP substrates is amenable to detection of intracellular PTP activity, thus precluding the development of cell-based PTP assays. There is an urgent need for new specific PTP assays, suitable to both enzyme-based and cell-based HTS for small molecule PTP inhibitors. We recently generated a novel fluorescent pTyr analog, phosphocoumaryl-amino-propionic acid (pCAP), which can be incorporated into peptides. Peptides containing pCAP are excellent and specific PTP substrates. pCAP-based PTP assays are highly sensitive and direct, and can be used to detect intracellular PTP activity. In this proposal we will optimize pCAP-peptides as substrates for novel, specific PTP assays suitable to enzyme-based and cell-based HTS of PTP inhibitors. We will show that pCAP-peptides have better specificity profiles than DiFMUP when used as PTP substrates in enzyme-based assays. We will also show that specificity of pCAP peptide can be further improved using a library-screening approach. Highly specific pCAP-peptides will then be used to validate an innovative cell-based PTP assay and optimized for HTS of small molecule PTP inhibitors. We will use the lymphoid tyrosine phosphatase (LYP) as our model PTP as our recent work renders LYP a novel drug target for human autoimmunity. We predict that our new cell-based PTP assay will provide a revolutionary paradigm in HTS for PTP inhibitors in both the academic and industrial setting.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK080165-05
Application #
8279475
Study Section
Instrumentation and Systems Development Study Section (ISD)
Program Officer
Pawlyk, Aaron
Project Start
2008-08-15
Project End
2014-05-31
Budget Start
2012-06-01
Budget End
2014-05-31
Support Year
5
Fiscal Year
2012
Total Cost
$308,188
Indirect Cost
$99,917
Name
La Jolla Institute
Department
Type
DUNS #
603880287
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Ahmed, Vanessa F; Bottini, Nunzio; Barrios, Amy M (2014) Covalent inhibition of the lymphoid tyrosine phosphatase. ChemMedChem 9:296-9
Thorson, Megan K; Puerta, David T; Cohen, Seth M et al. (2014) Inhibition of the lymphoid tyrosine phosphatase: the effect of zinc(II) ions and chelating ligand fragments on enzymatic activity. Bioorg Med Chem Lett 24:4019-22
Stanford, Stephanie M; Krishnamurthy, Divya; Kulkarni, Rhushikesh A et al. (2014) pCAP-based peptide substrates: the new tool in the box of tyrosine phosphatase assays. Methods 65:165-74
Stanford, Stephanie M; Ahmed, Vanessa; Barrios, Amy M et al. (2014) Cellular biochemistry methods for investigating protein tyrosine phosphatases. Antioxid Redox Signal 20:2160-78
Kulkarni, Rhushikesh A; Vellore, Nadeem A; Bliss, Matthew R et al. (2013) Substrate selection influences molecular recognition in a screen for lymphoid tyrosine phosphatase inhibitors. Chembiochem 14:1640-7
Kulkarni, Rhushikesh A; Stanford, Stephanie M; Vellore, Nadeem A et al. (2013) Thiuram disulfides as pseudo-irreversible inhibitors of lymphoid tyrosine phosphatase. ChemMedChem 8:1561-8
Karver, Mark R; Krishnamurthy, Divya; Bottini, Nunzio et al. (2010) Gold(I) phosphine mediated selective inhibition of lymphoid tyrosine phosphatase. J Inorg Biochem 104:268-73
Karver, Mark R; Krishnamurthy, Divya; Kulkarni, Rhushikesh A et al. (2009) Identifying potent, selective protein tyrosine phosphatase inhibitors from a library of Au(I) complexes. J Med Chem 52:6912-8